Miglustat

Evidence Level: L5

Predicted Indications: 10

Miglustat
Miglustat: From Gaucher Disease to Autosomal Ichthyosis Syndrome with Fatal Disease Course

## Pharmacist Assessment Report

Miglustat: From Gaucher Disease to Autosomal Ichthyosis Syndrome with Fatal Disease Course

One-Sentence Summary

Miglustat is an oral glucosylceramide synthase inhibitor, originally used for type 1 Gaucher disease. The TxGNN model predicts it may be effective for autosomal ichthyosis syndrome with fatal disease course, but no clinical trials and no publications currently support this prediction. It is a model-only signal (Evidence Level L5).

Quick Overview

Item	Content
Original Indication	Type 1 Gaucher disease (taken from the literature; the US label indication text was not provided)
Predicted New Indication	Autosomal ichthyosis syndrome with fatal disease course
TxGNN Prediction Score	99.83%
Evidence Level	L5
US Market Status	✓ Marketed
Number of NDAs	7 licenses (1 brand NDA, Zavesca; the rest are generic ANDAs)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the input. From general pharmacology, miglustat inhibits glucosylceramide synthase, which lowers the synthesis of glucosylceramide and related glycosphingolipids (substrate reduction therapy). Its efficacy in Gaucher disease is established, and mechanistically it may be applicable to other sphingolipid disorders.

Ichthyosis syndromes often involve disrupted epidermal lipid or ceramide metabolism, so a sphingolipid-pathway connection is conceivable. However, the specific molecular defect in this disease is unspecified, and the link is speculative. The high score should be read as a model output, not as evidence of benefit.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

US Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
NDA021348	Zavesca (Actelion Pharmaceuticals US)	Capsule	Not provided
ANDA209821	Yargesa (Edenbridge Pharmaceuticals)	Capsule	Not provided
ANDA208342	Miglustat (ANI Pharmaceuticals)	Capsule	Not provided
ANDA219111	Miglustat (Navinta)	Capsule	Not provided
ANDA219111	Miglustat (Zydus Pharmaceuticals USA)	Capsule	Not provided

All listed products are oral capsules.

Safety Considerations

Please refer to the package insert for safety information. The Evidence Pack contained no drug interaction records for miglustat.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on the model score alone. There are no trials or literature for this indication, the disease’s molecular defect is unspecified, and the mechanistic link is speculative.

Better-supported prediction in the same pack: Tay-Sachs disease (rank 7, score 99.75%, L2) is the only prediction with clinical evidence. It has miglustat trials in GM2 gangliosidosis (NCT00672022, NCT00418847, NCT03822013, NCT02030015) and a randomized late-onset study (PMID 19346952). However, that study and a 2023 systematic review (PMID 37209042) do not show a clear neurological benefit. It is best treated as a research question rather than a Go candidate.

To proceed, the following is needed:

FDA package insert warnings and contraindications (a blocking gap for safety screening)
Mechanism of action data from DrugBank
Identification of the specific genetic and biochemical defect in this ichthyosis syndrome, to test whether glucosylceramide synthase inhibition is relevant
Preclinical or literature evidence in ichthyosis models before any clinical consideration
Route compatibility assessment (oral capsule only is currently available)

This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.